BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.